The primary analysis in many randomized controlled trials focuses on the average treatment e↵ect and does not address whether treatment benefits are widespread or limited to a select few. This problem a↵ects many disease areas, since it stems from how randomized trials, often the gold standard for evaluating treatments, are designed and analyzed. Our goal is to learn about the fraction who benefit from a treatment, based on randomized trial data. We consider the case where the outcome is ordinal, with binary outcomes as a special case. In general, the fraction who benefit is a non-identifiable parameter, and the best that can be obtained are sharp lower and upper bounds on it. Our main contributions include (i) showing that the naive (plugin) estimator of the bounds can be inconsistent, in the case that support restrictions are made on the joint distribution of the potential outcomes (such as the no harm assumption); (ii) developing the first consistent estimator for this case; (iii) applying this estimator to a randomized trial dataset of a medical treatment to determine whether the estimates can be informative. Our estimator is computed using linear programming, allowing fast implementation. R and MATLAB software are provided (https://github.com/emhuang1/fraction-who-benefit).
Inequality in Treatment Benefits: Can We Determine if a New Treatment Benefits the Many or the Few?
Introduction
We aim to make inferences about the fraction of the population who benefit from a treatment. This fraction is defined in the potential outcomes framework. Each participant has two potential outcomes, one representing the participant's outcome if assigned to treatment and the other if assigned to control. The fraction who benefit is defined as the fraction of the population whose potential outcome under treatment is better than that under control. In other words, it is the fraction who would be better o↵ under treatment than under control.
The fraction who benefit is generally a non-identifiable parameter. This is due to the fundamental problem of causal inference, which is that we can observe only one of the potential outcomes for any individual (Holland, 1986) . However, sharp bounds on the fraction are identifiable (Williamson and Downs, 1990; Manski, 1997; Park, 2009, 2010; Kim, 2014) . We develop a new method to estimate bounds using randomized trial data, when the outcome is ordinal. The bounds are based on the marginal distributions of the potential outcomes and can also incorporate a prognostic baseline variable, support restrictions on the joint distribution of the potential outcomes, or both.
Our main contributions include (i) showing that the naive (plug-in) estimator of the bounds can be inconsistent in the case where support restrictions are made (such as the no harm assumption); (ii) developing the first consistent estimator for this case; (iii) applying this estimator to a randomized trial dataset of a medical treatment to determine whether the estimates can be informative. An advantage of the proposed estimator is that it can be computed using linear programming, i.e., the optimization of a linear objective function subject to linear equality and inequality constraints (Vanderbei, 2013) . Linear programming has readily available software that is computationally e cient. The lower and upper bound estimates are typically computed in under a second.
We apply our method to the MISTIE II (Minimally Invasive Surgery for Intracerebral Hemorrhage Evacuation Phase II) randomized trial (Morgan et al., 2008) , which compared a new surgical intervention for stroke to standard medical management. As an example of our results in one case, the lower and upper bound estimates on the fraction who benefit are 0.10 and 0.73 when the outcome is a rating of functional disability 180 days post-stroke, and 0.82 and 0.99 when the outcome is reduction in clot volume. Also, we conduct simulation studies to evaluate the bias and standard error of the bound estimators, as well as the performance of standard n-bootstrap and m-out-of-n bootstrap in constructing confidence intervals for the bounds.
Related work includes Manski (1997) ; Gadbury et al. (2004) ; Park (2009, 2010) ; Zhang et al. (2013) ; Kim (2014) ; Borusyak (2015) . Manski (1997) derives sharp bounds on the fraction who benefit, assuming no harm (i.e., for each individual, the potential outcome under treatment is not worse than under control) and without using the marginal distributions of the potential outcomes. Manski (1997) does not assume that treatment assignment is independent of the potential outcomes, unlike our context of a randomized clinical trial where this holds by design. Gadbury et al. (2004) derive bounds on the fraction harmed, given the marginal distributions of the potential outcomes, for a binary outcome. They use matched-pairs and extended matched-pairs designs to improve the bounds, while we use a simple randomized trial design and consider a prognostic baseline variable and/or support restrictions.
Using copula theory, Park (2009, 2010) derive sharp bounds on the fraction who benefit, given the marginal distributions of the potential outcomes. Kim (2014) derives another set of bounds through optimal transportation theory, which can incorporate support restrictions on the joint distribution of the potential outcomes. These bounds apply to continuous outcomes, while our bounds apply to ordinal outcomes. Both Park (2009, 2010) and Kim (2014) provide estimators for their bounds. Kim's method generally requires solving a non-convex optimization problem when a support restriction is made. Non-convex problems are much more computationally di cult to solve than linear programs, which are used by our method. Zhang et al. (2013) propose a method to directly estimate the fraction who benefit, assuming that the potential outcomes are conditionally independent of each other given a set of measured baseline covariates. Sensitivity analyses are used to address assumption violations. Our method allows support restrictions, a di↵erent type of assumption than conditional independence. Borusyak (2015) shows that, for a discrete outcome, one can use linear programming to compute bounds on the fraction who are strong responders (i.e., the fraction whose magnitude of individual treatment e↵ect exceeds a threshold), given the marginal distributions of the potential outcomes and assuming no harm. Borusyak does not address estimation of these bounds; in contrast, our main focus is estimation.
The organization of our paper is as follows. We provide background on the MISTIE II trial in Section 2. In Section 3, we define the bound parameters. In Section 4, we show that the plug-in estimator can be inconsistent and propose an alternative estimator which is consistent. We apply our estimator to the MISTIE II trial in Section 5, and present simulation results in Section 6. We discuss future research directions in Section 7.
MISTIE II Trial
The data to be analyzed is from MISTIE II, a recently completed Phase II randomized trial for intracerebral hemorrhage, a type of stroke that can impair cognitive/motor functions and cause death (Morgan et al., 2008) . The MISTIE II trial was designed to assess the e↵ec-tiveness of image-guided minimally invasive surgery (i.e., treatment), relative to standard medical care (i.e., control). There were 96 participants, with 54 assigned to treatment and 42 to control. The randomization ratio between study arms gave a higher likelihood of being assigned to treatment, yielding the higher proportion of treatment participants.
In MISTIE II, the primary outcome was a rating of functional disability at 180 days after stroke, measured by the modified Rankin Scale (mRS) (Quinn et al., 2009) . The mRS score is ordinal, defined as an integer between 0 and 6, with lower values corresponding to improved functioning (Cheng et al., 2014) . For example, 0 corresponds to no symptoms and 6 to death. The original analysis categorized a patient's outcome as successful if 180-day mRS  3. For the primary analysis comparing treatment versus control, the average treatment e↵ect (ATE) was used, i.e., the di↵erence in population proportions with a successful outcome. The estimate of ATE was 0.11 (95% CI: [-0.09, 0.29] ), using the 52 treatment and 38 control participants with recorded 180-day mRS scores.
For a patient or clinician, it could also be useful to know the fraction who benefit from treatment, with respect to functional disability at 180 days as measured by mRS. This is the fraction of patients who would have a better 180-day mRS score under treatment than under control. Since this ATE only considers mRS in two categories ( 3 or > 3), it ignores any benefit within a category, which in the MISTIE trial context is clinically meaningful. It also does not provide an upper bound on the fraction who benefit.
In general, the population ATE is not designed to give information about the fraction who benefit. For example, if the outcome is ordinal, the population ATE can be large while the fraction who benefit is small; this would occur if the majority get zero benefit while a minority have a large benefit.
Bound Parameters

Identifiable Components of Potential Outcome Distribution Based on Randomized Trial
Denote Y C and Y T as the potential outcomes under control and treatment, respectively. Suppose the outcome of interest is ordinal with L levels (i.e., 1, 2, .., L), ordered from least to most favorable. For MISTIE, the outcome is mRS score recoded in this order, such that L = 7, with 1 corresponding to death, and 7 to no symptoms. Let X be a prognostic baseline variable measured in the randomized trial. For each participant, define the vector including the baseline variable and both potential outcomes as V = (X, Y C , Y T ). We let P denote a generic, joint distribution on (X, Y C , Y T ) and let P 0 denote the true (unknown) distribution on these variables. We assume each participant's vector V is an independent, identically distributed draw from P 0 . Both values Y C and Y T are never simultaneously observed on the same patient (Holland, 1986) . Rather, we observe (X, A, Y ), where A is the randomized treatment assignment (1 if treatment, 0 if control) which is independent of V , and Y is the observed outcome corresponding to the treatment assigned, i.e., Y = AY T + (1 A)Y C .
Our goal is to learn about the fraction who benefit, i.e., the parameter = P (Y T > Y C ), despite never observing the full pair of potential outcomes for any participant. Although the fraction who benefit is non-identifiable, we can rule out certain possibilities based on the marginal distributions of Y C and Y T , which are identifiable. Denote F C and F T as the marginal distribution functions of Y C and Y T , respectively. The distribution F C is identifiable because F C (y) = P (Y C  y) = P (Y C  y|A = 0) = P (Y  y|A = 0) for any y, and F T is identifiable by the same principle. Section 3.2 presents bounds on , as a function of F C and F T . These bounds can be sharpened by incorporating a baseline variable X or by making assumptions about the joint distribution of (Y C , Y T ), discussed in Section 3.3.
Sharp Bounds on the Fraction who Benefit, with Neither
Baseline Variable nor User-defined Assumptions
We present sharp bounds on the fraction who benefit, given only F C and F T . Define ⇡ i,j as the fraction of the population with (
form an L x L matrix representing the joint distribution of the potential outcomes (JDPO), shown in Figure 1a for MISTIE. There, the row and column sums correspond to p C and p T , respectively, where p C (y) = P (Y C = y) and p T (y) = P (Y T = y) for any y.
We partition the population into three categories based on potential outcomes (Y C , Y T ): those for whom assignment to treatment (compared to control) would have no e↵ect, harm, or benefit. These categories correspond to the colored regions in Figure 1a , where the diagonal region (yellow) represents no e↵ect (Y T = Y C ), the lower region (red) represents harm (Y T < Y C ), and the upper region (green) represents benefit (Y T > Y C ). The parameter is the fraction of the population in the green region, i.e., the sum of ⇡ i,j over indices (i, j) with j > i. The value of , in general, is non-identifiable since for each individual we only observe one component of (Y C , Y T ), and therefore do not know which of the three aforementioned regions this individual belongs to.
Let l (F C , F T ) and u (F C , F T ) denote the sharp lower and upper bounds on , given only F C and F T , i.e., the best possible bounds for that could be obtained if F C , F T were known. We say a joint distribution P 0 on (Y C , Y T ) is consistent with a pair of marginal distribution functions F C , F T if the marginal distribution of Y C under P 0 equals F C and the marginal distribution of Y T under P 0 equals F T . The bound parameter l (F C , F T ) is formally defined as the infimum of the fraction who benefit, among all joint distributions P 0 on (Y C , Y T ) consistent with F C and F T , i.e.,
The bound u , which can be derived analogously, equals (1) with sup in place of inf, and (2) with max in place of min. It follows from the form of (2) that l (F C , F T ) and u (F C , F T ) can be represented as linear programs. We sometimes drop their dependence on F C , F T when it is clear from context. Referring to Figure 1a , if one were to calculate P j>i ⇡ i,j for every possible matrix of ⇡ i,j 's with row and column sums consistent with p C and p T , the bounds l and u would be the minimum and maximum among them. Borusyak (2015) uses this concept to derive bounds on the fraction who are strong responders. In the binary case (L = 2), l and u simplify to max 0, p T (2) p C (2) and min p C (1), p T (2) , respectively (Gadbury et al., 2004) .
General Formulation of Sharp Bounds on the Fraction who Benefit
We generalize the bound formulation to incorporate a baseline variable, user-defined assumptions, or both. These can narrow the bounds because they o↵er new information. We consider a baseline, i.e., pre-randomization, variable that is categorical and conjectured to be prognostic for (i.e., correlated with) the outcome. For instance, a prognostic baseline variable in MISTIE II is stroke severity, measured by the NIH Stroke Scale (NIHSS) (Kreutzer et al., 2011) . Define X as a baseline variable with K possible values (i.e., x 1 , .., x K ; K < 1). Let p X be the probability mass function of X, i.e.,
Based on X, one can stratify the total population into K subpopulations, with weights given by p X . For each k, let F k C and F k T be the marginal distribution functions of Y C and Y T , respectively, for subpopulation k. That is, for any y,
Another way to potentially improve bounds on the fraction who benefit is to incorporate user-defined assumptions about P based on subject matter knowledge. We focus throughout on assumptions of the form P (Y C = i, Y T = j) = 0 for pairs (i, j) specified by the user. These support restrictions on the joint distribution of (Y C , Y T ) are encoded by the indicator function g : L ⇥ L ! {0, 1} that maps each potential outcome pair (y C , y T ) to 0 if the pair is assumed not possible, and 1 otherwise. Equivalently, g(i, j) = 0 encodes the assumption that ⇡ i,j = 0. The support restrictions we consider in our application (Section 5) include:
• Restriction on harm: The harm of treatment is at most
No harm (i.e., ⇡ i,j = 0 if i > j) is a special case.
• Restriction on benefit: The benefit of treatment is at most
Figure 1b illustrates the restriction on benefit with d = 3 for the MISTIE case. For conciseness, we sometimes refer to user-defined assumptions as restrictions. We assume the restrictions, i.e., the function g, is prespecified and known. Let R be the subclass of joint distributions
In other words, R is the subclass of joint distributions on (Y C , Y T ) that satisfy the user-defined assumptions. If there are no user-defined assumptions, then g maps to 1 for any (y C , y T ), and R includes all joint distributions on (Y C , Y T ). We make the following assumption:
denote the sharp lower and upper bounds on , respectively, incorporating the baseline variable X and user-defined assumptions R. These bounds are functions of R and the identifiable components of P (X, Y C , Y T ) in a randomized trial where study arm is assigned independent of X, i.e., the components {F
The upper bound R,X u is (6), with sup in place of inf. Let R l denote the lower bound with restrictions R but ignoring the baseline variable X, i.e., (5)-(6) with {F
Similarly, let X l denote the lower bound with the baseline variable but no restrictions R, i.e., (5)-(6) with R omitted. Analogous definitions apply for the upper bounds. The bounds l , u from Section 3.2 are equivalent to (5)-(6) with R omitted and {F
Each of the bound parameters
, p X of P ; the bound l is a function of P through the (less informative) components F C , F T . We suppress the dependence of these parameters on P for conciseness.
Incorporating a baseline variable or restriction leads to a larger or equal lower bound, and smaller or equal upper bound, as expressed in Theorem 1, proved in Appendix A: Theorem 1. Consider any user-defined assumptions R, baseline variable X, and joint dis-
where each bound parameter is evaluated at P .
An analogous claim holds for the upper bound parameters. Appendix A and all following appendices can be found in the Supplementary Materials at the end of this document.
Restrictions R may be inconsistent with a set of marginal distributions {F
, p X . In this case, the bound parameter (6) is undefined, since the set of distributions on the right hand side is empty. This cannot occur if the true distribution P 0 is consistent with both R and {F
, p X . However, the user may impose restrictions R that are incorrect, i.e., are inconsistent with the true distribution P 0 , in violation of Assumption 1 above. We refer to this as model misspecification. It can lead to the bound parameters evaluated at P 0 , such as R,X l (P 0 ), being undefined, as discussed in Section 5. One can also derive bounds on the fraction of a subpopulation who benefits. For any k, denote l,k and u,k as the sharp lower and upper bounds on the fraction of subpopulation k who benefit, given its marginal distributions and the user-defined assumptions:
In the above display,
u,k is (7) with sup in place of inf. We show in Appendix B that (7) can be represented as a linear program, similar to (2). As proved in Appendix C, R,X l and R,X u are weighted sums of R,X l,k and R,X u,k , with weights equal to p X (x k ); i.e.,
Bound Estimators
We discuss estimators for the bounds defined in Section 3.3, using data from a randomized trial with n participants. We make the assumption below on the data generating distribution:
Assumption 2. (i) For each participant m = 1, . . . , n, her/his potential outcome vector
Above, (ii) is justified by randomization and we assume the randomization probability . It is straightforward to modify these estimators to handle the special cases of bound parameters that ignore baseline variables and/or have no restrictions.
Plug-in estimator
Given the user-defined assumptions R, the bound parameters
, p X . One may consider plug-in (also called substitution) estimators of these parameters where sample proportions are used in place of these components. Define the sample proportions
where 1(E) is the indicator function taking value 1 if E occurs and 0 otherwise. Define the corresponding plug-in estimators
These estimators are the solutions to the corresponding linear programs with empirical proportions substituted for {F
and b R,X u,k is the solution to the corresponding maximization problem, for each k. If support restrictions are made, the above estimators can be inconsistent even when the support restrictions are true. These estimators may be undefined (i.e., no joint distribution is both consistent with the restrictions and the empirical marginal distributions within strata of the baseline variable), with non-negligible probability, for large n. As a simple example, consider the case where there is no baseline variable, the outcome is binary (failure = 1, success = 2), and the true, unknown joint distribution P 0 on (Y C , Y T ) satisfies the null hypothesis of no individual treatment e↵ect, i.e., P 0 (Y C = Y T ) = 1. Then the true marginals satisfy P 0 (Y C = j) = P 0 (Y T = j) for each j 2 {1, 2}. Let the user-defined assumptions R represent no harm, i.e., the event (Y C = 2, Y T = 1) is assumed to have probability 0. This set of restrictions R is consistent with P 0 . There is only one joint distribution on (Y C , Y T ) consistent with R and the marginal distributions F C , F T of P 0 , i.e., P 0 itself. Equivalently, only one matrix (the true JDPO) satisfies the constraints in (2). Therefore, the upper and lower bound parameters at P 0 satisfy (
The plug-in estimators of these bounds are undefined with probability approximately 1/2, for large sample size n when the randomization probability ✓ = 1/2. The reason
is consistent with both the marginal distributions b F C , b F T and R; in this case, b R l and b R u are undefined. The probability
as n goes to infinity (Appendix D), implying that b R l and b R u are undefined with probability approximately 1/2 even for large sample sizes n.
In general, the plug-in estimators b R,X l and b R,X u may fail to converge in probability in "boundary" cases, i.e., when there is some k for which the linear programs for to be undefined with nonzero probability at arbitrarily large n. Boundary cases can only occur if restrictions R are made. They can occur under the null hypothesis of no individual treatment e↵ect and the no harm assumption, so they are of practical relevance. In some (but certainly not all) trials, it can be a reasonable assumption that the treatment does not cause harm, so this restriction is practically relevant for analyzing such trials. One solution that can handle boundary cases is to ignore the restriction and estimate ( l , u ) or ( X l , X u ). However, this may be a waste of valuable subject matter knowledge because a restriction can substantially improve the bounds, e.g., in the above example (
To address this, we propose an alternative estimator that can incorporate restrictions and that is consistent even in boundary cases.
Proposed estimator
We propose an estimator that relaxes the constraints regarding b , as:
where
is computed by solving the following sequence of linear programs:
. (16) The estimator 
F T are defined as (9)- (10), except with X m = x k omitted. The estimator l for the lower bound l is obtained by applying both of the above modifications. The corresponding upper bound estimators are obtained similarly.
As proved in Appendix E, R,X l and R,X u are consistent, i.e., they converge to the corresponding bound parameters as n goes to infinity. By a similar proof, it can be shown that the estimators which ignore baseline variables and/or have no restriction are consistent. Theorems 1 and 2 imply that if P 0 is consistent with R, then the probability limits of the estimators
l , l satisfy the inequalities in Theorem 1. This means that including a baseline variable or restriction can only improve (or leave unchanged) the limiting value of the bound estimators, leading to larger or equal lower bounds and smaller or equal upper bounds. However, at a given sample size, neither the plug-in estimators from Section 4.1 nor the above estimators are guaranteed to satisfy the corresponding inequalities in Theorem 1.
MISTIE Application using Bound Estimators from
Section 4.2
Using data from the MISTIE II trial, we estimate bounds on the fraction of intracerebral hemorrhage patients who benefit from image-guided minimally invasive surgery (treatment), relative to standard medical care (control), with respect to 30-day mRS score, 180-day mRS score, and reduction in clot volume. We use the estimators from Section 4.2. Tables 1-3 in the Supplementary Materials give all bound estimates. The Supplementary Materials can be found at the end of this document.
30-and 180-day mRS Scores
For both 30-and 180-day mRS scores, four types of sharp lower/upper bounds are estimated: (i) no baseline variables or user-defined assumptions, (ii) user-defined assumption only, (iii) baseline variable only, (iv) both a user-defined assumption and a baseline variable. These correspond to bound parameters ( l , u ),(
), respectively, as defined in Section 3.3.
The user-defined assumptions we consider are Benefit  d levels and Harm  d levels. The value d is varied from 1 to 5 for the former, and 0 to 5 for the latter. (d is not set to 0 for the former since that restriction would imply the fraction who benefit is 0). The baseline variable is stroke severity, where a stroke is classified as non-severe if the baseline NIHSS score  20 and severe otherwise (Kreutzer et al., 2011) .
The bound estimators are those from Section 4.2. When estimating bounds for a given outcome (e.g., 180-day mRS), we exclude participants who are missing that outcome; for both mRS outcomes, we exclude the single patient with missing baseline NIHSS score. The resulting sample sizes are 53 treatment and 39 control participants for 30-day mRS score, and 52 treatment and 37 control participants for 180-day mRS score. To estimate bounds (i) and (ii), we use the empirical distributions of the mRS scores under treatment and control, shown in the top panel of Figure 2 . To estimate bounds (iii) and (iv), we use the empirical distributions after stratifying by subpopulation, shown in the bottom two panels of Figure 2 . The proportion in each subpopulation is estimated by the corresponding sample proportion of MISTIE II participants (after excluding participants as described above). We discuss methods that adjust for missing outcomes in Section 7, which is an area of future research.
Figures 3a and 3b present the bound estimates for 30-and 180-day mRS scores, respectively. With neither user-defined assumptions nor baseline variable, the pair of estimated bounds ⇥ l , u ⇤ on the proportion who benefit is [0.07,0.61] for 30-day mRS, and [0.10,0.73] for 180-day mRS. The widths of these estimated bounds, i.e., the di↵erence between the upper and lower bound estimates, are 0.54 and 0.63, respectively. Imposing user-defined assumptions can narrow the width of the estimated bounds. For the 180-day outcome, the width narrows by 0.17 under Benefit  1, 0.31 under Harm  1, and 0.55 under no harm, relative to no user-defined assumptions. These reductions are absolute di↵erences in widths, as is the case throughout the paper.
Incorporating the baseline variable narrows the width of the estimated bounds by 0.19 for 30-day mRS, and 0.12 for 180-day mRS (under no restrictions). However, the baseline variable does not have a large impact in every case. Under the restriction R = {Harm  2}, it narrows the width only by 0.02 for 180-day mRS score; also, the upper bound estimate with the baseline variable ( R,X u = 0.63) is slightly above that without the baseline variable ( R u = 0.62). This can occur since, as mentioned in Section 4.2, the bound estimators need not obey the corresponding inequalities in Theorem 1.
In Figure 3 , there are five sets of restrictions under which✏ > 0 or at least one✏ k > 0, indicating the marginal distribution constraints were relaxed in the bound estimators. We point out two features. First, these bound estimates may not be contained within the interval formed by estimates under a less stringent restriction. For example, for 30-day mRS, the lower bound estimate under R = {no harm} is R l = 0.03, which is below the lower bound estimate R 0 l = 0.07 under the weaker restriction R 0 = {Harm  1}. This behavior is either due to a boundary case (see Section 4), small sample performance of the estimator, or the data generating distribution not satisfying the no harm assumption. In the third case, the bound estimators may be inconsistent.
Second, for a given restriction, an upper bound estimate can be much larger, or a lower bound estimate much smaller, with the baseline variable than without it. For example, under the restriction R = {no harm}, the upper bound estimate without the baseline variable is R u = 0.18, while the corresponding estimate with the baseline variable is R,X u = 0.50, for the 180-day mRS outcome. By Theorem 1, the true upper bound can only decrease or stay the same with the addition of a baseline variable, i.e., R u (P 0 ) R,X u (P 0 ), if the user-defined assumptions are true (i.e., if P 0 consistent with R). One possible cause for the behavior we observe is that the no harm assumption is false, in which case R u could be well-defined while R,X u is not. Then R u could be much smaller than R,X u , even at large sample sizes. Such a discrepancy could be used as a test of the assumptions R, which is an area of future research.
In addition to the fraction who benefit for the total population, one may be interested in the fraction for a specific subpopulation, i.e., P (Y T > Y C |X = x k ). Here, X represents baseline stroke severity, with x 1 =nonsevere and x 2 =severe. Figure 4 presents the estimated bounds for each subpopulation, i.e., Imposing user-defined assumptions can improve the bounds, which can be reflected in the bound estimates. For example, under Harm  1, the estimated bounds of the non-severe subpopulation are [0.04, 0.26] for 30-day mRS score. Confidence interval widths (described in Section 6) will generally be wider than for the bounds on the total population, due to smaller sample sizes.
Reduction in Clot Volume
Another outcome in MISTIE II is reduction in clot volume (RICV), the di↵erence between clot volume at baseline and end of treatment, as defined in Mould et al. (2013) . RICV is a continuous variable in units of mL. In MISTIE II, the observed RICV range was [-2.57, 75 .45] mL under treatment, and [-14.86, 12 .01] mL under control. To apply our method, we discretize RICV into an ordinal variable with six levels. For a reduction of y mL, the corresponding level is 1 if y < -5, 2 if -5  y < 0, 3 if 0  y < 5, 4 if 5  y < 10, 5 if 10  y < 15, and 6 if y 15. The ordinal approximation may not reflect small benefits (i.e., individual benefits within a category), but does capture benefits of large enough magnitude to transition between categories. Below, we refer to the ordinal variable as RICV.
Since higher levels correspond to better outcomes, the fraction who benefit is the fraction who would have a higher RICV under treatment than under control. We estimate the same types of sharp bounds (i)-(iv) as in Section 5.1. The restrictions R that we consider are Benefit  d and Harm  d. The value d is varied from 1 to 4 for the former, and 0 to 4 for the latter. The baseline variable is an indicator of the baseline clot volume being above or below the median baseline clot volume of the MISTIE II participants (43.2 mL).
All MISTIE II participants are included, and there are no missing data for RICV or the baseline variable. The sample sizes for the RICV analysis are 54 treatment and 42 control participants. To estimate bounds (i) and (ii), we use the empirical distributions of the RICV's under treatment and control, shown in the top panel of Figure 5 . The empirical distribution for treatment first-order stochastically dominates that for control. While all control patients had RICV 5 or less, 74% of treatment patients had RICV 6. This suggests that treatment has a major e↵ect on RICV. To estimate bounds (iii) and (iv), we use the empirical distributions after stratifying by subpopulation, shown in the bottom two panels of Figure 5 . There is also stochastic dominance of treatment within each subpopulation. Figure 6a presents the estimated bounds on the fraction who benefit for the total population. With neither the baseline variable nor restrictions, the estimated bounds on the proportion who benefit are [0.82, 0.99]. As in the mRS results, the baseline variable and user-defined assumptions narrow the estimated bounds for RICV. For example, with the baseline variable and the assumption of Benefit  4, the width of the estimated bounds narrows by 0.05. This improvement may seem small, but is substantial as a proportion of the estimated bound width when neither assumptions nor the baseline variable is used (0.17).
The restrictions on harm are not included on the x-axis because the estimated bounds are the same as under no assumptions. This is because there are matrices that satisfy the no harm assumption, are consistent with the empirical marginal distributions, and have fraction who benefit equal to 0.82 or 0.99. The bound estimates for Benefit  1 and Benefit  2 are much wider than for the less stringent restrictions. In these cases, large values of ✏ and ✏ k (ranging from 0.22 to 0.62) occur. Large values of ✏ or ✏ k raise doubts about the validity of the user-defined assumptions; it is an area of future work to construct formal hypothesis tests for this problem, to determine with high confidence whether a large observed value of ✏ or ✏ k can be explained by chance variation or is due to violations of the user-defined assumptions. Bounds under false assumptions are not guaranteed to contain the true fraction who benefit.
Finally, we estimate bounds on the fraction who benefit for each subpopulation. The estimates are shown in Figure 6b . Without user-defined assumptions, the estimated bounds on the proportion who benefit are [0.81, 0.96] for those with low baseline clot volume (< 43.2 mL), and [0.86, 1.00] for those with high baseline clot volume ( 43.2 mL).
Simulation Studies
We conduct simulation studies to evaluate the bias and standard error of the estimators from Section 4.2. We also study the performance of n-and m-out-of-n bootstrap in constructing 95% confidence intervals (CI's) for the bounds.
Two outcomes are separately considered: RICV and a binary outcome. In both cases, no baseline variable is used. For RICV, the data generating distributions under treatment and control are set to be the empirical distributions in MISTIE II, shown in the top panel of Figure  5 . No user-defined assumptions are made. The bound parameters are ( l , u ) = (0.82, 0.99). For the binary outcome, the data generating distribution is P 0 (Y T = y) = P 0 (Y C = y) = 1 2 for y 2 {1, 2}. We consider the cases where no assumptions are made, and where the no harm assumption is made. The bound parameters are ( l , u ) = (0, 0.5) and (
where R = {no harm}. We refer to the three cases as RICV, binary (no restrictions), and binary (no harm).
For each case, we simulate 10,000 randomized trials each with n participants ( n 2 in treatment, n 2 in control). We consider n = 100, 500, and 1000, respectively. In each simulated trial, the estimators from Section 4.2 are computed. Also, we compute a two-sided 95% CI for the lower bound and a separate two-sided 95% CI for the upper bound, using n-and m-out-of-n bootstrap. For n-bootstrap (percentile method), we generate 10,000 replicated data sets by resampling n participants, with replacement, from the simulated trial data. For m-out-of-n bootstrap, the procedure is the same, except each of the 10,000 replicated datasets is generated by sampling m participants with replacement, where m  n. The value m is chosen using the procedure in Section 2 of Bickel and Sakov (2008) , setting tuning parameter q = 0.95 to create a list of candidate values and generating 5,000 replicated datasets for each candidate value. We implement m-out-of-n bootstrap since it can in some cases have better asymptotic properties than n-bootstrap (Bickel and Sakov, 2008) . Table 1a shows the estimated bias and standard error of the bound estimators, as a function of the trial size n. Bias is negligible in the RICV case. For the binary outcome, the magnitude of bias is approximately 0.04 at n = 100, 0.02 at n = 500, and 0.01 at n = 1000. Bias corrections have been developed for bound estimators involving continuous outcomes (Fan and Park, 2009; Kim, 2014 ). An area of future work is to develop a bias correction for our estimator. Table 1b shows the empirical coverage probability of the nominal 95% CI's constructed using n-and m-out-of-n bootstrap, as a function of trial size n. For the binary outcome, the CI's tend to have overcoverage compared to the nominal value of 95%. Coverage is ⇡ 99% for m-out-of-n bootstrap, and ⇡ 97% for n-bootstrap. One exception is the CI's for u in the binary (no restriction) case. In this case, both techniques under-cover u , with m-out-of-n bootstrap at ⇡ 93% coverage and n-bootstrap at ⇡ 90% coverage, even at n = 1000. For RICV, empirical coverage is generally close to the nominal coverage. An exception is that mout-of-n and n-bootstrap have empirical coverage rates of only 84% and 82%, respectively, for u , when n = 100. In Table 1b , m-out-of-n bootstrap generally has higher empirical coverage probability than n-bootstrap.
Fan and Park (2010) implement the n-and m-out-of-n bootstrap at sample sizes from 1000 to 4000. In their simulations, the coverage probabilities of the two techniques are similar and approximately the nominal coverage. In our simulations, the coverage rates of the two approaches are less similar and we observe some undercoverage even at n = 1000.
In Table 1b , average CI width is slightly higher for m-out-of-n bootstrap than for nbootstrap. The average CI width also varies by case and by the bound being considered. For example, in the RICV case, average CI width tends to be smaller for the upper bound than for the lower bound.
Our results show that n-and m-out-of-n bootstrap can be unreliable when n = 100. However, m-out-of-n bootstrap has empirical coverage rates above or only slightly below the nominal rate when n = 500 or 1000.
Discussion
In the MISTIE application, the interval corresponding to the lower and upper bound estimates is narrow for RICV, and wide for both the 30-and 180-day mRS scores. This gives a proof of concept example showing that depending on the outcome, the proposed estimator of the fraction who benefit can be informative.
Incorporating a prognostic baseline variable or user-defined assumption can improve the bounds. Open problems are to identify which baseline variables are most e↵ective at narrowing the bounds and to determine the optimal number of subpopulations on which to stratify, based on the trial size. If more strata are used, the bounds may become narrower, but estimation of F k C and F k T (k = 1, .., K) is less precise. We seek a balance between narrow bounds and low variance.
Our data application shows that restrictions on benefit and harm can improve the bound estimates. For example, for 180-day mRS, we have ( l , u ) = (0.10, 0.73), in contrast to ( R l , R) u = (0.10, 0.18) when R = {no harm}. The latter bound estimates, though highly informative due to the lower and upper bound estimators being much closer together, are only valid if the no harm assumption is true (which needs to be based on subject matter knowledge). This can be appropriate in some clinical settings but not in others. It is possible to generate evidence against the restriction being true by considering the estimator✏ k , which in our application raises substantial doubts. Though certain deviations from the restrictions may be detectable, other types of deviations may not be. One may view the bound estimators under nested sets of more stringent restrictions as being a sensitivity analysis to examine how much information on the fraction who benefit would result under di↵erent types of assumptions on harm/benefit.
We impose restrictions on benefit and harm separately, but they can also be imposed jointly. Since linear programming can incorporate any linear equality or inequality constraints on the ⇡ i,j 's, it is possible to explore, e.g., the e↵ects of other types of assumptions than support restrictions, such as monotonicity of ⇡ i,j 's (e.g., ⇡ 3,1  ⇡ 3,2 ).
Our simulation results show that n-and m-out-of-n bootstrap can have undercoverage when n = 100. An area of future work is to identify an alternative method which can achieve the nominal coverage at n = 100.
It is possible to extend our approach to handle missing outcomes, such as by using double robust estimators of the marginal distributions instead of the empirical marginal distributions ignoring missing outcomes. Under the missing at random assumption, one could use estimators of the marginal distribution functions that adjust for baseline confounders, e.g., using methods of Diaz et al. (2015) .
Mould, W. A., Carhuapoma, J. R., Muschelli, J., Lane, K., Morgan, T. C., McBee, N. A., et al. (2013) . Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Figures and Tables   (a) Under no assumptions
(b) Under restriction on benefit with d = 3 Figure 1 : Joint distribution on the potential outcomes (JDPO). Yellow corresponds to no individual treatment e↵ect, red to harm, and green to benefit. For conciseness, restrictions were excluded from these figures if their corresponding grey and black bars were identical to those under no user-defined assumptions. For grey bars, the value of ✏ is listed above the bar, if it is nonzero. For black bars, ✏=* indicates that one or more of the ✏ k 's is nonzero. For bars corresponding to the subpopulation with non-severe stroke, the value of ✏ 1 is listed above the bar, if nonzero. For bars corresponding to the subpopulation with severe stroke, the value of ✏ 2 is listed above the bar, if nonzero. 
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Appendix A: Proof of Theorem 1 Theorem 1. Consider any user-defined assumptions R, baseline variable X, and joint distribution P on (X, Y C , Y T ) that is consistent with R. Then we have
Proof. Let F C , F T , and p X be the marginal distributions of Y C , Y T , and X, respectively, under P . For each k = 1, .., K, let F k C and F k T be the conditional distributions of Y C and Y T given X = x k , under P . We have the following:
Notice that all of these bound parameters are well-defined since P is consistent with
, p X , and R. Inequalities (2) and (6) hold because the constraint that P 0 is consistent with R has been removed on the right sides, so the inf is being taken over an increased set leading to smaller or equal value. Inequalities (4) and (8) hold because the inf is being taken over an increased set on the right sides, since any P 0 consistent with all
, p X is also consistent with F C , F T , as shown below:
, p X (which are the marginal distributions corresponding to P ), then for any y,
so P 0 is consistent with F C . Using an analogous proof, it can be shown that P 0 is consistent with F T . Since
R,X l,k and R,X
u,k as Solutions to Linear Programs
For any k, the lower bound
is the solution to a linear program because:
u,k is (14), with max in place of min, so it is also a solution to a linear program.
where each parameter is evaluated at P .
Proof. The bounds R,X l and R,X u are defined as:
for any y and k, and p X (x k ) = P (X = x k ) for any k. For each k, we have that:
, and { R,X u,k } K k=1 are solutions to linear programs, inf can be replaced with min, and sup with max in the four definitions above.
We now show that P K k=1
That is, there exist joint distributions P l and P u on (X, Y C , Y T ) that (i) are consistent with R, (ii) are consistent with {F k C , F k T } K k=1 and p X , and (iii)
that is consistent with R,F k C , and F k T , and satisfies
are the minimum and maximum of (15), respectively. We do a proof by contradiction. Suppose that the minimum of (15) is smaller than P K k=1
. This would imply that, for some k, there exists a distribution
l,k . However, this contradicts the definition of R,X l,k . Thus,
is the minimum of (15). It can be shown analogously that P K k=1
is the maximum of (15). We conclude that
j>i takes the value 1 if j > i and 0 otherwise. Define A as the matrix that satisfies:
Let f (b) denote the optimal value of the linear program as a function of b. Define:
When b = b n , LP is equivalent to the linear program for 
Proof. We assume the reader has familiarity with linear programming terminology. (For an overview of linear programming relevant to our proof, please see Chapter 6 of Dantzig and Thapa (2006) .) Without loss of generality we can drop the x 0 term in the linear program (16) since these constraints can be incorporated into the set of inequalities Ax  b. Consider the dual linear program: max y b T y, subject to A T y = c, y 0.
It is bounded and feasible at b = b ⇤ and at b = b 0 , which follows from the conditions in the lemma. Let V ⇤ denote the set of vertices of the dual linear program, which is non-empty, finite, and only depends on A and c (and does not depend on b). Since the optimal value of the dual problem occurs at a vertex, it equals max{y T b : y 2 V ⇤ }, for any vector b for which the linear program is bounded and feasible (which includes the cases b = b ⇤ and b = b 0 ). By strong duality, for each b 2 {b 0 , b ⇤ }, the optimal value of the primal (original) linear program equals the optimal value of the dual linear program, and therefore
where the last inequality follows from the Cauchy-Schwartz inequality. The lemma is proved for C = max y2V ⇤ kyk 2 , which is finite since V ⇤ is non-empty and has a finite number of elements.
Lemma 2. Let P 0 be the true joint distribution on (X, Y C , Y T ). Suppose P 0 is consistent with R and Assumptions 1 and 2 hold. Then ✏ k p ! 0 for any k, as n ! 1.
Proof. In this proof, we will show that lim n!1 P 0 (|✏ k 0| > ⌘) = 0 for any ⌘ > 0. Choose any k = 1, .., K. Fix n 2 N. Consider the following linear program, referred to as LP: min x c T x, subject to Ax  b, x 0. Define x and c as:
⇤ , where 0 1⇥L 2 is a row vector of length L 2 containing only zeroes. Define A as the matrix that satisfies:
Let f (b) be the optimal value of LP as a function of b. Define: 
It follows from the Weak Law of Large Numbers that b n converges to b ⇤ in probability, and so the right side of the above display converges to 0 as n ! 1, completing the proof of the lemma. Table 2 : Estimated Bounds on the Fraction who Benefit, with respect to 180-day mRS Score. The bound estimates in (a) are for the entire population, and those in (b) are for each subpopulation.
(a) For the population Table 3 : Estimated Bounds on the Fraction who Benefit, with respect to Reduction in Clot Volume (ordinal). The bound estimates in (a) are for the entire population, and those in (b) are for each individual subpopulation.
(a) For the population
